FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:1704-1705 December 21, 1995 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

In patients with acute viral infection, therapy with systemic antiviral agents can save lives, as in the case of Lassa fever, or prevent the progression of disease, as in influenza or herpes simplex infection.¹ The challenge is greater when these agents are used over the long term to suppress or eradicate chronic viral infections with such pathogens as hepatitis B or C virus, cytomegalovirus, or human immunodeficiency virus (HIV).¹ This issue of the Journal contains two articles that show how a new nucleoside agent, lamivudine, can be helpful in two of these chronic infections.^2,3 This drug is a purified (-)enantiomeric . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Dufour, D. R., Lott, J. A., Nolte, F. S., Gretch, D. R., Koff, R. S., Seeff, L. B. (2000). Diagnosis and Monitoring of Hepatic Injury. II. Recommendations for Use of Laboratory Tests in Screening, Diagnosis, and Monitoring. Clin. Chem. 46: 2050-2068 [Abstract] [Full Text]